No Data
Plus Therapeutics Announces 1-for-25 Reverse Stock Split
Express News | Plus Therapeutics Announces Reverse Stock Split
Express News | Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to Its Board of Directors
Press Release: Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to Its Board of Directors
Plus Therapeutics Price Target Maintained With a $3.00/Share by D. Boral Capital
Plus Therapeutics Is Maintained at Buy by D. Boral Capital